Proficiency testing by State and Federal agencies is an ongoing actMty of clinical laboratories and an occasional source of anxiety; strict statistical evaluationsof "snapshot" laboratoryvalues are inappropriateand medical-needs criterIa should be used. The quality of laboratoryresultslargely depends on availabletechnology. Fortunately,for mostof the common clinical chemistryanalytesthere has been a steady reduction of Imprecisionduringthe past 20 years. Proficiency testing may have been the stimulusfor this improved performance. Medical-needs criteria differ, depending on the testing goal. For proficiencytesting, population screening criteria are appropriate,e.g., the College of American Pathologistsfixed criteriafor the common tests. Strictercriteriaare needed for short-term(Inpatient) and long-term(outpatient) monitoring of laboratory data. Explicit proficiency-testing limitsare given here for nine of the common ciinlcalchemistry tests for each of the three medical-needs criteria describedabove. The limitsconsidertotal error-I.e., biasfrom the believed correct value, and imprecision.Rather broad limits are acceptable for the commonly performed enzyme tests when used for screening purposes. 
tory. Many experienced laboratorians contend that external
PT cannot be the sole indicator of performance; however, PT can indeed serve to trigger further investigation into a potential problem (7, 8) .
The consensus of laboratorians at a CAP conference on PT (9) was that a single ("snapshot") laboratory-produced value is inadequate for assessing general laboratory performance. The same situation applies in patients: a single abnormal value is rarely used in making a diagnosis but generally, if untoWard, is the impetus for further investigation. Values outside of the mean ± 2 SD-i.e., outside of 12 . for the peer group-are deemed to be unsatisfactory. An attractive feature is the utter simplicity for the evaluators of the survey; however, the arbitrary exclusion of about 5% of laboratories is wrong most of the time (11). Also, such peergroup evaluations are deficient, because they tend to ignore bias. We have come a long way since the findings of Belk and Sunderman in 1947 (12 (13) . Their methods appear to be more powerful. However, they are still based on PT participants' statistics. Medical-needs criteria are not used in their scheme.
Intra-individual variability
and use to which laboratory data are put should play a role in detemilning the requisite analytical quality of the laboratory data (10). The difficulties with medical-needs criteria are subjectivity, ex cathedra statements, and assumptions based on incomplete or unavailable data. Medical-needs criteria for laboratory performance are necessarily arbitrary and based on "soft" data, creating a difficult scenario for laboratory regulators and their apparent greater comfort in relying on "hard" data such as participant-derived statistics (2) . Nevertheless, the general consensus of authors who have wrestled with this question is that medical-needs criteria should determine acceptable laboratory performance (10). The tool must fit the task, and purely statistical evaluations cannot be the sole arbiters of laboratory performance. Figure l(a-e) depicts some of the internal quality-control experience in our laboratory over the last 21 years. Each figure shows a unique phenomenon, and all the common clinical chemistry tests performed by us have a pattern resembling one of these five. The concentrations of the analytes in the control sera were reasonably constant over the 21-year period and were at or near decision points. The reason we show these data is to illustrate time trends of imprecision. The data are not a product of special handling or repeat analyses. It was the best the laboratory could do with the available materials, equipment, and people.
An HistorIcal Vw of Testing Imprecision

Bilirubin.
In Figure la , bilirubin at concentrations of 8 to 12 mg/L shows a pattern of improving, then worsening, precision. Between 1967 and 1979, assays were carried out with manual diazotized sulfanilic acid procedures; until 1972, it was that of Malloy-Evelyn (15) and then a version of the Jendrassik-GrOf method was used (16). The monthly mean CV was about 8% until 1979, when we began using the automated method on the DuPont aca. The latter gave consistently more precise results, and the CVs declined to a mean of about 4%, a marked improvement. In early 1984, we began assaying total bilirubin in the Astra instrument (Beckman, Brea, CA 92621), and the CV increased to about 15%. Part of this increase was ascribable to a lower concentration of biirubin in the control, i.e., 8 mg/L vs 10 mg/L as used earlier. Although we were concerned about this deterioration of precision, we made a subjective decision to accept the values based on the pressure to reduce costs and increase automation. At the time, we judged that an uncertainty of 3 mgfL for bilirubin at a total concentration of about 10 mgfL was medically acceptable. We really had no basis for this conclusion.
Calcium. Calcium, at 1.8 to 2.2 mmol/L (Figure lb) , shows the second type of pattern of generally improving CVs that apparently plateau at about 3%. The manual Calcein titrimetric method was used until 1970 and was clearly unsatisfactory, but it was the least bad of all the then-available methods. An automated atomic absorption procedure (17) used between 1970 and 1982 was better, although the method showed large swings in precision from month to month. We used the aca between 1983 and 1985, which provided clearly lower CVs, and in 1985, we started using an Astra for calcium assays, with some minor loss of precision.
Cholesterol. Cholesterol at 1800 to 2200 mg/L (Figure ic) shows the third and most desirable type of pattern: a steady decrease in imprecision. From 1967 to 1978, we used a manual FeC13 method (18), and the variability of the method was large indeed! There is also a suggestion of long- . The ABA-100 was a consistent and precise performer, and the decrease in imprecision was significant. We now have a mean monthly CV of about 3%, which meets a recently recommended criterion for cholesterol testing (20) .
Creatinine.
CV data for creatinine at concentrations of 10 to 12 mg/L (Figure id) 
What is Medically Acceptable Error?
Several authors have struggled with the problem of medically acceptable error, a topic summarized elsewhere (10, 22). The somewhat capricious but largely correct answer is: "it depends!" We divide this question into two subtopics: what is acceptable error for population screening-the least stringent limits-and what is allowable for detecting short-term trends in hospitalized patients-probably the most stringent need. Other types of medical needs are assumed to fall between these two extremes.
Medically Acceptable Error in Population Screening
What are the requirements of the laboratory to identify individuals with a biochemical disorder? Assume, as did Harris (23) , that the well and sick have biochemical data with gaussian distributions and equal variances, and that the two groups overlap. (For example, see 10, Figure 6 .) A gaussian distribution is the exceptional case (24) . However, as Harris (23) has shown, it is an extremely useful assumption, and can be used to make generalizations of the effect of changes in Ca (i.e., the %CV) on the clinical sensitivity and specificity. To be consistent with Harris' model, we use his terminology, i.e., Ca and Cb; the latter is the intrapersonal biological variation.
With some exceptions such as cholesterol (25) , the population histograms of the well and sick are largely unknown.
A decision value at the overlap point produces an equal number of false positives and false negatives when the numbers of well and of sick are the same. Also, the sensitivity, specificity, and diagnostic efficiency (DE) of the test at the overlap point are the same. DE is the percentage of all results that are true results. With this model, the effect on DE of changes in precision can be estimated. The effect of bias from the true value depends on the direction of the bias relative to the random error. If the bias and random error are in the same direction, the effect can be mild to disastrous, and can render the test result meaningless. Bias can usually be dealt with as is discussed below. Also, with knowledge of the prevalence of disease, the predictive values of an abnormal test result (PV(+)), and a normal test result (PV(-)) can be calculated, and the alterations of PV(+) and PV(-) that are caused by changing Ca and Cb can be estimated. PV(+) is the probability of disease with an abnormal test, and PV(-) is the probability of absence of disease with a normal test.
The general case. We followed Hams' method in making calculations of the effect of changing precision, and some general results are shown in Figure 3, a and b. Figure 3a illustrates the concept and is for equal populations of well and sick and the case where the overlap occurs at a Z = 1.00, i.e., the overlap is exactly 1 SD from the means of each population. Here, there is substantial overlap, and a 16% false-positive and false-negative rate. Various percentages of intrapersonal biological variation (Cb) are shown, and the effect of changing precision is plotted.
Several conclusions can be drawn from (25) . Here the overlap is such that decreasing Ca would substantially improve the DE of serum cholesterol testing.
Figure 3b is like Figure 3a; however, the overlap of the well and sick is at Z = 1.64, and is much smaller, yielding only 5% false-positive and false-negative values at the intersection of the population histograms. A decrease in Ca affects DE only when Cb is less than about 5%. Above a Cb of about 5%, decreasing Ca does not improve DE, and efforts to reduce Ca would be Wasteful.
The intuitive notion is correct that a large Ca is tolerable with well-separated populations of well and sick. It may be possible to make economic and diagnostic decisions based on data similar to those shown in Figure 3 a and b. If Cb is 10% and Ca is 8% and there is a 5% overlap of the populations, little improvement in DE is achieved by trying to decrease Ca still further.
Effect of prevalence. In Figure 3 , a and b, a 50% prevalence of the sick is assumed; the prevalence is always smaller in population biochemical screening programs. We show in Table 1 In a subsequent report (28) , they found the prevalence of hypercalceniia owing to hyperparathyroidism to be about 0.1%. How well does the laboratory have to perform to identify patients with hypercalcemia? Table 3 shows PV(+) data for serum calcium at various prevalences. With a Cb of 2.4% (29) , Z = 1.00 and prevalence of 0.2%, the Ca must be 2% or smaller to identify correctly 80% of patients who have true hypercalcemia during a screening exercise. There is a large change in PV(+) in going from a Ca of 4% to 2% at Z = 1.00 and at all prevalences. Assuming a Z of 1.64 or larger, then a Ca of 4% is probably satisfactory. Implicit here is the increasing PV(+) with a patient's increasing serum calcium. We chose the overlap of the well and sick as the decision point as a matter of convenience and to be in accord with the earlier work of Harris (23) . Clearly, the higher the patient's serum calcium, the greater the allowed Ca can be to detect true hypercalcemia; i.e., the medically acceptable error increases with increasing serum calcium. 1C6 data for Z = 1.00; data for Z = 1.64 data shown in parentheses. C,, = 6.6% (29) . bpredlofe valueof positivetest at prevalence shown.
Cholesterol.
Data for serum cholesterol are shown in Table 4 . Given the considerable recent publicity on serum cholesterol and the recommendations that clinical laboratories should strive for a Ca of 3% or less, it is most appropriate to consider what is a medically acceptable error for cholesterol. In an unselected outpatient population of adult men and women (n = 200), we observed a 27% prevalence of serum cholesterol values >2400 mgIL; others observed a prevalence of 25% (30). The Cb for cholesterol is about 6.6% (29) , and the data for PV(+) at several prevalences are given in Table 4 . The overlap of serum cholesterol values is substantial for those not at risk vs those at risk (25) . An assumption of Z = 1.00 at the overlap is reasonable, therefore the gain in PV(+) at a 25% prevalence in going from a Ca of 6% to 4% to 2% is not very large. A Ca of 4% to 6% looks medically acceptable. Tighter precision requirements appear to be unwarranted based on the above considerations.
Creatinine. There is a less than 1% prevalence of undiagnosed pathology leading to a serum creatinine that exceeds 15 mg/L. In an outpatient population seen here, after patients with chronic heart or kidney diseases are excluded, we estimate that less than 2% of patients have a creatinine >15 mgIL. Assuming a prevalence of 1% and a 5% overlap (Z = 1.64), then a medically acceptable error is in the range of 4% to 6%. Currently, most laboratories in the CAP Chemistry Survey report Ca's of between 7% and 10% for a creatinine value that is within normal limits. Serum creatinine is a test with unmet medical needs, and the current level of C5 is too large in nearly all laboratories. More effort is needed by the manufacturers and users of the creatinine test to reduce imprecision.
Glucose. The prevalence of undiagnosed glucose intolerance of any cause in population screening studies is about 2% to 4% (31). Assuming a prevalence of 5% and a 5% overlap, then a medically acceptable error is about 8% to 10%. Most laboratories have C5's for glucose of <6% at 1000 mg/L. Serum glucose is a test where medical needs have been largely met.
Trend Detection
The detection of within-patient trends in clinical analytes places the greatest demands on the clinical laboratory. The problem is estimating true within-patient trends in the milieu of all the perturbations that can affect the final results. We follow Harris' (23) approach in estimating whether a trend is statistically significant, defined by us as Z = 1.64 (P <0.05) for a one-sided test.
After renal transplantation, the serum creatinine receives continuous and critical scrutiny as an index to both acute and chronic rejection (32). Assuming Ca is 10% at a creatinine of 15 mg/L, can a change from 15 to 17 mgfL be detected? The statistical test we chose is whether Z is greater than the critical value, 1.64. Z is calculated from the change in creatinine and the analytical SD of the method as fbllows:Z1 = 115-171 /(SD V).Jntheflrstexample,Z1 We developed some general tables, using the above relationships to simplify the concept. For three values in a trend, the percent difference between the mean of the first two and the third value can be calculated readily as shown above, and is defined here as "delta." Assuming certain values of C5, the Z statistic can be calculated, and the results for three values in a series are shown in Table 5 . If we use 1.64 as the critical Z value, the data reveal that to detect a delta of 4%, a C5 of <2% is required. At the other extreme, a delta of 16% can be detected with a Ca as large as about 8%. Table 6 shows a similar scheme, but is for four successive values in a trend. The deltas here are the percent difference between the fourth value and the mean of the first three results. The intuitive notion is correct that it is easier to detect a genuine trend with four values as compared with three. Also, a greater Ca is tolerable when there are more sequential values at hand, the changes are greater, and if they are in the same direction.
intuitively Acceptable Error Acceptable error should be based on how tests are used clinically. We describe a case here where expert opinion and intuition can serve well in describing medically acceptable error. In adults, results for the commonly performed serum enzyme tests-e.g., alkaline phosphatase, aspartate aminotransferase, and creatine kinase-when used in population screening studies, are usually viewed by clinicians as "normal," slightly to moderately increased, or significantly increased, For an enzyme test with result in the reference range, a large Ca is acceptable. If, for example, the upper reference limit is 100 U/L and the patient's enzyme result is 40 U/L, an acceptable error could be a Ca of 100%! This may strike many as extreme error, but any values for the enzyme test between 0 and 80 U/L would generally elicit the same response from the clinician. At 100 U/L, we would allow a C5 of 50%; any values between 50 and 150 U/L are expected to receive the same response, i.e., normal or slightly increased. At 200 U/L, we would allow a C5 of 25%, and even this broad limit may be too strict given how the enzyme tests are used in screening studies.
The above intuitive logic is the basis of the fixed criteria used to evaluate enzyme data in the CAP Comprehensive Chemistry Survey (33). To require a Ca of, say, 25% at 50 UIL for acceptable PT is overly rigid and unwarranted, given how the results are used for screening populations. There is really no perceived difference between 0 and 100 UI L for nearly all the commonly performed enzyme tests assuming an upper reference limit of 100 UIL. For uses other than population screening-e.g., assays for serum enzymes in suspected acute myocardial infarction cases-the above criteria are too liberal and CVs of 10% to 15% would be required.
Conclusions
A medically acceptable error for laboratory tests must be defined in the context of test use. Bias from the true value must be considered, and the combination of bias and random error constitutes the total medically acceptable error. Bias of certain common analytes can be dealt with by proper standardization.
Definitive methods exist for serum Ca, Cl, Fe, K, Li, Mg, Na (34), cholesterol, glucose, urea, and uric acid (35) , and excellent estimates of the true values for these analytes are produced by certain peer groups in the CAP Chemistry Survey. Such results can be used to decrease or eliminate bias in most instances.
For population screening, what factors demand the best accuracy that the laboratory can produce? Conversely, where does mandating a reduction in imprecision yield no benefit? If there is considerable overlap of the well and sick populations, then reducing imprecision yields improvements in the diagnostic efficiency. Also, if the biological variability is small, if the prevalence of disease is low, and if the cost to society of a missed diagnosis is unacceptably high, then the greatest accuracy possible is required of the laboratory.
More uncertainty in laboratory data is acceptable when the population distributions for healthy and sick are well separated, the intrapersonal biological variability is large, and the prevalence of disease is high. The laboratory is of course not omnipotent, and repeat determinations will improve the yield of diagnostic information.
For trend detection, inpatients (short-term trends) or outpatients (long-term trends), better accuracy is needed than for population screening.
We have shown here that short-term trends can be detected as early as in the third test of a monotonous series if the laboratory imprecision is low. Consistent trends are generally obvious by the fourth or fifth test, and more error is acceptable.
Evaluation of PT results by peer-group statistics is invalid, as Ross (10) has amply shown. Evaluations based solely on statistical analyses of participants' results are easy to do but hard to justify; they ignore medical-needs criteria, the only reasonable yardstick today. We recommend that the CAP-fixed criteria for the common analytes in clinical chemistry (Table 7) be used for PT testing evaluation and as total error limits for population screening. We suggest that these limits be halved for long-term trend detection and approximately quartered for short-term trend recognition (see Table 7 ). These limits are arbitrary but reasonable, given the evidence shown here and elsewhere (10). We believe the three sets of limits define reasonable goals for within-laboratory proficiency and satisfy three types of medical needs.
